PET for Sarcomas Other Than Gastrointestinal Stromal Tumors
|
|
- Noah McLaughlin
- 7 years ago
- Views:
Transcription
1 PET for Sarcomas Other Than Gastrointestinal Stromal Tumors Guy C. Toner, a,c Rodney J. Hicks b,c a Division of Haematology and Medical Oncology and b Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia; c Department of Medicine, St Vincent s Medical School, University of Melbourne, Melbourne, Australia Key Words. Sarcoma PET scanning Response assessment Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article. Abstract Positron emission tomography (PET) is increasingly used to diagnose, grade, and stage different types of tumors and to assess tumor response to therapy. Metabolic data acquired by fluorine--fluorodeoxyglucose ( FDG)-PET may facilitate accurate grading of sarcomas and have prognostic value when combined with other grading methods and various clinical/radiological features. In addition, FDG-PET is currently being evaluated in several cancer types for its utility in biopsy guidance. Whole-body FDG-PET also appears to be superior to other imaging modalities in detecting bone metastases in certain sarcoma patients. New PET tracers currently being investigated include F-fluorothymidine ( F-FLT) and F-misonidazole. F-FLT can help to determine tumor growth, rather than tumor shrinkage, which could be used to evaluate treatment response in sarcomas. PET imaging offers invaluable information to help maximize the clinical benefit of patients with sarcoma. This article reviews the use of PET in sarcoma management and its potential applications in the near future. The Oncologist 2008;13(suppl 2):22 26 Introduction Positron emission tomography (PET) has wide-ranging utility in sarcoma, including staging, assessment of prognosis, monitoring response, and potentially to customize treatment regimens [1 4]. Fluorine--fluorodeoxyglucose ( FDG)-PET is well suited to detecting the inherent heterogeneity of these tumors. The utility of PET in tumor grading, biopsy guidance, staging and restaging, and response evaluation and monitoring in sarcoma patients is discussed. Utility of PET for Tumor Grading An association between FDG uptake and sarcoma tumor grade was first noted in 1988 [5]. FDG-PET avidity has been shown to increase with tumor grade in both bone and soft tissue sarcomas: the glycolytic metabolic activity of high-grade tumors is higher than that of low-grade or benign tumors [6]. In addition to histopathological grade, FDG- PET standardized uptake value (SUV) was also demonstrated to be associated with cellularity, mitotic activity, MIB labeling index, and p53 overexpression in various bone and soft tissue sarcomas [6]. Thus, metabolic data acquired by FDG-PET may facilitate accurate grading and have prognostic value in the sarcoma setting. To a certain extent, FDG-PET may be used to differentiate benign from malignant sarcomas. Significant differences in the differential uptake ratio, a quantitative index of glucose metabolism, in benign masses and malignant sarcomas have been noted by several researchers [7, 8]. However, the definition of malignant has been problematic, as has the type of sarcoma being evaluated. Furthermore, different groups have obtained conflicting results using the metabolic rate of FDG (MRFDG) as a parameter to distinguish between benign and malignant sarcomas [9 11]. Correspondence: Guy Toner, M.D., Peter MacCallum Cancer Institute, Medical Oncology, St. Andrews Place, East Melbourne, Australia Telephone: ; Fax: ; guy.toner@petermac.org Received August 20, 2007; accepted for publication December 11, AlphaMed Press /2008/$30.00/0 doi: /theoncologist.13-S2-22 The Oncologist 2008;13(suppl 2):
2 Toner, Hicks MRFDG does not appear to be useful for grading certain bone tumors, such as giant cell tumors, which typically show a relatively high SUV. In contrast, this methodology has been successfully used to distinguish among grade I, II, and III soft tissue sarcomas [10]. While FDG-PET alone may not be sufficient for grading sarcomas, it does have the potential to provide complementary information when coupled with other grading modalities and with various clinical/radiological features. Evaluation of FDG uptake may also have potential prognostic value. In patients with gastrointestinal stromal tumors, reductions in the FDG-PET maximum SUV have been shown to correlate with longer time to progression [12]. In a study of 74 adult patients with soft tissue sarcoma who underwent preoperative FDG-PET imaging, SUV was found to be somewhat predictive of recurrencefree survival [13]. Patients with SUVs <1.59, 1.59 to <3.6, and 3.6 had 5-year recurrence-free survival rates of 66%, 24%, and 11%, respectively. While these results are promising, further studies are required to determine whether PET information can be used as an independent prognostic variable in this patient population. Figure 1. CT, FDG-PET, and fused FDG-PET/CT images of a patient with a large left thigh mass consistent with liposarcoma. FDG-PET was used during biopsy to target the region with highest metabolic activity. Abbreviations: FDG-PET, fluorine--fluorodeoxyglucose positron emission tomography; CT, computed tomography Utility of PET for Biopsy Guidance Both PET and computed tomography (CT) are very useful for biopsy guidance. As an example, Figure 1 demonstrates combined PET/CT findings in a case with a large left thigh mass with features consistent with liposarcoma. FDGPET was used during biopsy to guide the treating physician to the highest metabolic region, which allowed confirmation that this was a high-grade tumor. In this patient, multiple s.c. metastases were also detected by PET. Thus, by guiding biopsy toward the most biologically significant regions of large masses, FDG-PET can reveal information about a lesion that cannot be obtained through other imaging modalities. The use of FDG-PET in biopsy is currently being investigated in several cancer types, and may prove invaluable in several settings, including sarcomas. Utility of PET for Staging and Restaging Two independent studies reported that the sensitivity and specificity of FDG-PET for the detection of pulmonary metastases from various types of sarcoma were 50% 86.7% and 98% 100%, respectively, while the sensitivity and specificity of spiral CT of the chest were 75% 100% and 96.4% 100%, respectively [14, 15]. However, FDGPET has a higher sensitivity than CT for soft tissue metastases, and it can also be used to identify false-positive CT masses. The two groups of researchers agreed that CT and FDG-PET are both needed to accurately define the extent of disease during initial staging as well as during follow-up. Our own experience with combined PET/CT scanning over the past 3 years suggests that CT scanning is particularly helpful in localizing small lung metastases wherein partial volume effects lead to insufficient signal on PET to allow a confident diagnosis of malignancy. Conversely, for larger nodules, the presence of high uptake at other sites of disease but not in the lung nodule makes a metastatic basis very unlikely. In contrast, whole-body FDG-PET appears to be superior to other imaging modalities for detection of bone metastases in certain sarcoma patients. Compared with bone scintigraphy, FDG-PET was associated with a higher sensitivity (100% versus 68%), specificity (96% versus 87%), and accuracy (97% versus 82%) in 38 patients with histologically proven malignant primary Ewing s sarcoma [16]. Interestingly, although FDG-PET also appeared to have some value in the detection of osseous masses from osteosarcomas, it appeared to be less sensitive than bone scintigraphy in these patients. FDG-PET is also very helpful in assessing possible local recurrence and performing restaging. Detection of local recurrence is often difficult because of disturbance of the normal anatomy by previous surgery and any subse-
3 24 quent radiotherapy. Unlike some other imaging modalities, FDG-PET is not disabled by the metal susceptibility or metal beam hardening artifacts that may result from previous treatments. Several studies have indicated the high accuracy of FDG-PET for detecting late local recurrence in sarcoma patients [17 21]. Utility of PET in Response Evaluation and Monitoring The utility of FDG-PET in monitoring response has been recently demonstrated to be superior to that of CT for predicting outcome in patients with non-small cell lung cancer (NSCLC) [22]. CT and other structural imaging modalities have substantial limitations in the lung and pleura, such as irregular tumor shapes that are difficult to measure, poor contrast at the interface between tumor and normal tissue, and obstruction by radiation pneumonitis [22, 23]. In a direct head-to-head comparison, the utility of FDGPET and CT in assessing response and thereby survival in patients with NSCLC who received either radical radiotherapy or chemotherapy was evaluated. The study authors concluded that a single, early, post-treatment PET scan could significantly (p <.0001) predict survival, while CT results failed to do so [22]. FDG-PET may have similar response evaluation potential in other cancers, including sarcomas. Figure 2. FDG-PET and merged FDG-PET/CT images of a patient with an osteosarcoma of the left femur that was treated with neoadjuvant chemotherapy. The scans demonstrate a dramatic reduction in metabolic activity in the tumor after chemotherapy. Abbreviations: FDG-PET, fluorine--fluorodeoxyglucose positron emission tomography; CT, computed tomography. PET for Other Sarcomas The predictive value of PET scanning has been investigated for evaluating histological response following neoadjuvant chemotherapy in patients with osteosarcoma [24 26]. The case presented in Figure 2 shows that residual metabolic activity following neoadjuvant chemotherapeutic treatment of a leg osteosarcoma can be visualized using FDG-PET. In a prospective study that evaluated the utility of FDG-PET in assessing response to neoadjuvant chemotherapy in patients with osteosarcoma, Schulte and colleagues demonstrated a strong correlation between a reduction in tumor glucose metabolism following therapy and the histologic grade of tumor regression [24]. In 25 of 27 patients, pre- and post-treatment tumor-to-background ratios (TBRs) of FDG uptake could be used to discriminate responders from nonresponders. Thus, FDG-PET provides a promising tool for noninvasive evaluation of neoadjuvant chemotherapy response in osteosarcoma. Ideally, PET scanning will be used in the near future to detect differential responses to different neoadjuvant chemotherapeutic compounds, which might facilitate patient-specific tailoring of neoadjuvant treatment and postoperative therapy. However, this type of information must be obtained through the cooperation of several research groups through well-designed clinical trials. In contrast to the current use of PET immediately before and after completion of treatment only, there is potential value in performing PET scans several times throughout treatment, as illustrated in Figure 3. This approach might allow individual assessment of response to Figure 3. Proposed clinical trial model for evaluating the utility of FDG-PET in predicting response in osteosarcoma. (A): Use of FDG-PET during a neoadjuvant sarcoma treatment regimen would allow correlation of PET response with histologic response. (B): Proposed use of FDG-PET during neoadjuvant sarcoma treatment regimen. More frequent use of FDG-PET might allow assessment of response to individual components of the treatment regimen. Abbreviations: FDG-PET, fluorine--fluorodeoxyglucose positron emission tomography; CDDP/ADM, cisplatin and doxorubicin; MTX, methotrexate. OTncologist he
4 Toner, Hicks 25 the different chemotherapy components of treatment. As a result, information obtained through PET scanning during therapy might potentially change a patient s treatment, ultimately affecting his or her chances of remission and survival. Future Directions: New PET Tracers While FDG PET can be used along with CT to reveal the location and malignant potential of abnormal tissue masses, PET imaging has the potential to yield additional information about tumors that could further improve diagnosis and individually tailor cancer treatment. Several alternative PET radiopharmaceuticals are currently being investigated, both preclinically and in early clinical trials, which have the potential to reveal the growth rate, oxygen use, drug resistance properties, and blood supply of tumors. Examples of new PET tracers being investigated for use in sarcoma as well as other cancers include F-fluorothymidine ( F- FLT) and F-misonidazole ( F-MISO). F-FLT is an analogue of the nucleotide thymidine, and is therefore used as a marker of DNA synthesis. When used before treatment and soon after treatment begins, F-FLT may help determine the extent to which a tumor s growth is being slowed in response to therapy. This is particularly relevant for sarcoma, in which the use of newer cytostatic agents leads to a slower rate of tumor growth rather than tumor shrinkage. F-FLT-PET may allow changes in cell proliferation to be observed much earlier and to a much greater extent than FDG-PET. F-MISO is a marker of tumor hypoxia, which can lead to cellular responses that can potentially raise a tumor s resistance to therapy. Recent results have shown that F-MISO-PET may be useful for predicting survival in patients with head and neck cancer [27]. Conclusions In sarcoma, PET scans provide useful complementary information that must be interpreted in the overall context of the patient s imaging and other evaluations. PET can be used for grading of disease and differentiating between benign and malignant disease, biopsy evaluation, staging and restaging, assessing local recurrence, and therapeutic monitoring. However, further studies are required to improve quantitation of response, because SUVs and TBRs are at best semiquantitative, and comparison among different sites and use in clinical trials will require additional study. Finally, the potential advantages of identifying new radiopharmaceuticals such as FLT and F-MISO suggest that PET scanning will play an even larger role in the diagnosis and treatment of sarcomas in the future. References 1 Hicks RJ, Toner GC, Choong PF. Clinical applications of molecular imaging in sarcoma evaluation. Cancer Imaging 2005;5: Eary JF, O Sullivan F, Powitan Y et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: A retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29: Feldman F, van Heertum R, Manos C. FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 2003;32: Schulte M, Brecht-Krauss D, Heymer B et al. Grading of tumors and tumorlike lesions of bone: Evaluation by FDG PET. J Nucl Med 2000;41: Kern KA, Brunetti A, Norton JA et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988;29: Folpe AL, Lyles RH, Sprouse JT et al. (F-) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6: Adler LP, Blair HF, Makley JT et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991;32: Griffeth LK, Dehdashti F, McGuire AH et al. PET evaluation of softtissue masses with fluorine- fluoro-2-deoxy-d-glucose. Radiology 1992;2: Nieweg OE, Pruim J, van Ginkel RJ et al. Fluorine--fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37: Eary JF, Conrad EU, Bruckner JD et al. Quantitative [F-]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998;4: Kole AC, Nieweg OE, Hoekstra HJ et al. Fluorine--fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998;39: Holdsworth CH, Manola J, Badawi RD et al. Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST). J Clin Oncol 2004;22(suppl 14):197s. 13 Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A et al. Prognostic significance of preoperative [-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 2005;241: Lucas JD, O Doherty MJ, Wong JC et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br 1998;80: Franzius C, Daldrup-Link HE, Sciuk J et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: Comparison with spiral CT. Ann Oncol 2001;12: Franzius C, Sciuk J, Daldrup-Link HE et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: Comparison with bone scintigraphy. Eur J Nucl Med 2000;27: Franzius C, Daldrup-Link HE, Wagner-Bohn A et al. FDG-PET for detection of recurrences from malignant primary bone tumors: Comparison with conventional imaging. Ann Oncol 2002;13: Garcia R, Kim EE, Wong FC et al. Comparison of fluorine--fdg PET and technetium-99m-mibi SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996;37:
5 26 PET for Other Sarcomas 19 el-zeftawy H, Heiba SI, Jana S et al. Role of repeated F- fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma. Cancer Biother Radiopharm 2001;16: Bredella MA, Caputo GR, Steinbach LS. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentgenol 2002;179: Johnson GR, Zhuang H, Khan J et al. Roles of positron emission tomography with fluorine--deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin Nucl Med 2003;28: MacManus MP, Hicks RJ, Matthews JP et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21: Werner-Wasik M, Xiao Y, Pequignot E et al. Assessment of lung cancer response after nonoperative therapy: Tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 2001; Schulte M, Brecht-Krauss D, Werner M et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999;40: Franzius C, Sciuk J, Brinkschmidt C et al. Evaluation of chemotherapy response in primary bone tumors with F- FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000;25: Nair N, Ali A, Green AA et al. Response of osteosarcoma to chemotherapy. Evaluation with F- FDG-PET scans. Clin Positron Imaging 2000;3: Schwartz DL, Rajendran J, Yueh B et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004;130: The Oncologist
False positive PET in lymphoma
False positive PET in lymphoma Thomas Krause Introduction and conclusion 2 3 Introduction 4 FDG-PET in staging of lymphoma 34 studies with 2227 Patients CT FDG-PET Sensitivity 63 % 89 % (58%-100%) (63%-100%)
More informationPET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
More informationBEYOND 18 F-FDG: INTRODUCTION TO NEW RADIOPHARMACEUTICALS
BEYOND F-FDG: INTRODUCTION TO NEW RADIOPHARMACEUTICALS Asti Mattia Nuclear Medicine Department Santa Maria Nuova Hospital, Reggio Emilia, Italy SUMMARY: F-Labelled Choline analogues. Comparison between
More informationPET. Can we afford PET-CT. Positron annihilation. PET-CT scanner. PET detection
PET-CT Can we afford PET-CT John Buscombe New technology Combines functional information-pet anatomical information-ct Machine able to perform both studies in single imaging episode PET imaging depends
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationPET/CT in Breast Cancer
PET/CT in Breast Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria Overview Introduction Locorregional
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationInterview with David Djang, MD On PET Scan in Oncology: Principles and Practice
Interview with David Djang, MD On PET Scan in Oncology: Principles and Practice By Howard (Jack) West, MD May, 2009 Hello and welcome to the GRACE audio podcast on PET scanning. This one is with Dr. David
More informationPET/CT: Basic Principles, Applications in Oncology
PET/CT: Basic Principles, Applications in Oncology Mabel Djang, HMS III Overview PET Basics and Limitations PET/CT - Advantages and Limitations Applications of PET/CT in oncology Summary 2 Principles of
More informationThe Need for Accurate Lung Cancer Staging
The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives
More informationMalignant Pleural Diseases Advances Clinicians Should Know F Gleeson
Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant
More informationPET POSITIVE PLEURAL PLAQUES DECADES AFTER PLEURODESIS: MESOLTHELIOMA? Ellen A. Middleton 1. Jonathan C. Daniel 2. Kenneth S.
PET POSITIVE PLEURAL PLAQUES DECADES AFTER PLEURODESIS: MESOLTHELIOMA? Ellen A. Middleton 1 Jonathan C. Daniel 2 Kenneth S. Knox 1 Kathleen Williams 1 Departments of Medicine 1 and Surgery 2, University
More informationHERC Coverage Guidance Advanced Imaging for Staging of Prostate Cancer Disposition of Public Comments
Table of Contents Commenters... 1 Public Comments... 2 References Provided by Commenters... 6 Commenters Identification Stakeholder A Medical Imaging & Technology Alliance (MITA), Arlington, VA [Submitted
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More informationIn Practice Whole Body MR for Visualizing Metastatic Prostate Cancer
In Practice Whole Body MR for Visualizing Metastatic Prostate Cancer Prostate cancer is the second most common cancer in men worldwide, accounting for 15% of all new cancer cases. 1 Great strides have
More informationADJUVANT TREATMENT CLINICAL EVALUATION NEOADJUVANT TREATMENT
te: Consider Clinical Trials as treatment options for eligible patients. Referral to a center with both pediatric oncology and orthopedic surgery is essential. CLINICAL EVALUATION This practice algorithm
More informationLung cancer is not just one disease. There are two main types of lung cancer:
1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available
More informationDetection of local residual tumor after laryngeal cancer treatment using FDG-PET
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 21, No. 1, 9 13, 2007 Detection of local residual tumor after laryngeal cancer treatment using FDG-PET Ai OE,* Joji KAWABE,* Kenji TORII,* Etsushi KAWAMURA,*
More informationTable of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
More informationObjectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
More informationThoracic 18F-FDG PETCT
Thoracic 18F-FDG PETCT RAD Magazine, 41, 482, 13-16 Dr Allanah arker Specialist registrar radiology Dr Nagmi Qureshi Consultant cardiothoracic radiologist Papworth Hospital, Cambridge email: allanahbarker@nhs.net
More informationLung cancer forms in tissues of the lung, usually in the cells lining air passages.
Scan for mobile link. Lung Cancer Lung cancer usually forms in the tissue cells lining the air passages within the lungs. The two main types are small-cell lung cancer (usually found in cigarette smokers)
More informationDisease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200
GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung
More informationPET/CT in Lymphoma. Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto
PET/CT in Lymphoma Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto Outline 1. Introduction: PET/CT, how does it work? 2.Current
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationMedullary Renal Cell Carcinoma Case Report
Bahrain Medical Bulletin, Vol. 27, No. 4, December 2005 Medullary Renal Cell Carcinoma Case Report Mohammed Abdulla Al-Tantawi MBBCH, CABS* Abdul Amir Issa MBBCH, CABS*** Mohammed Abdulla MBBCH, CABS**
More informationContinuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7
Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7 Authors Ronald C. Walker 1,2, Tracy L. Brown 3, Laurie B. Jones-Jackson
More informationA new predictive algorithm for aiding clinical decision-making in lung cancer
Better Care. Faster A new predictive algorithm for aiding clinical decision-making in lung cancer Y Kogan, I Sela, Y Kheiffetz, M Kleiman, Z Agur, Optimata Ltd., O Liran, N Peled, Sheba hospital, I Lazarev,
More informationImage. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.
Neoplasms of the Ear and Lateral Skull Base Image 3.11.1 SW What are the three most common neoplasms of the auricle? 3.11.2 SW What are the four most common neoplasms of the external auditory canal (EAC)
More informationComparison of Threshold-Based Segmentation Methods on Pre- and Post- Therapy PET Scans
M. Phillips, S.F. Barrington, D.L.G. Hill, P.K. Marsden 1 Comparison of Threshold-Based Segmentation Methods on Pre- and Post- Therapy PET Scans Michael Phillips 1 Michael.Phillips.1@city.ac.uk Sally F.
More informationPost-PET Restaging Cancer Form National Oncologic PET Registry
Post-PET Restaging Cancer Form National Oncologic PET Registry Facility ID #: Registry Case Number: Patient Name: Your patient had a PET scan on: mm/dd/yyyy. The PET scan was done for restaging of (cancer
More informationSelection of Response Criteria for Clinical Trials of Sarcoma Treatment
Selection of Response Criteria for Clinical Trials of Sarcoma Treatment Scott M. Schuetze, a Laurence H. Baker, a Robert S. Benjamin, b Renzo Canetta c a Department of Internal Medicine, Division of Hematology/Oncology,
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More information1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT
1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT Learning that your pet has a diagnosis of cancer can be overwhelming. We realize that your pet
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationUse of FDG-PET in differentiating benign from malignant compression fractures
Skeletal Radiol (2008) 37:405 413 DOI 10.1007/s00256-008-0452-5 SCIENTIFIC ARTICLE Use of FDG-PET in differentiating benign from malignant compression fractures Miriam A. Bredella & Brendan Essary & Martin
More informationLow-dose CT Imaging. Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital
Lung Cancer Screening with Low-dose CT Imaging Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital Despite recent declines in the incidence of lung cancer related to the
More informationThere are 2 types of clinical trials that are of interest to the. The Clinical Trials Network of the Society of Nuclear Medicine
The Clinical Trials Network of the Society of Nuclear Medicine Michael M. Graham, PhD, MD The Clinical Trials Network of the Society of Nuclear Medicine was formed to provide quality assurance of both
More informationNon-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationFDG-PET/CT and SPECT for cancer staging. Executive summary INFORMES DE EVALUACIÓN DE TECNOLOGÍAS SANITARIAS AETSA INFORMES, ESTUDIOS E INVESTIGACIÓN
FDG-PET/TC y SPECT para la estadificación oncológica Estadificación del cáncer colorrectal, identificación del nódulo pulmonar solitario y la re-estadificación del linfoma. Informe corto FDG-PET/CT and
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationTreating Thyroid Cancer using I-131 Maximum Tolerable Dose Method
Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method Christopher Martel, M.Sc., CHP Lisa Thornhill,, NRRPT, RT(NM) Boston University Medical Center Thyroid Carcinoma New cases and deaths in
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More informationSummary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
More informationNEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER
Media Release April 7, 2009 For Immediate Release NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER London, Ontario Improved hybrid imaging techniques developed
More informationRadiation Therapy in the Treatment of
Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
More informationBrain Tumor Treatment
Scan for mobile link. Brain Tumor Treatment Brain Tumors Overview A brain tumor is a group of abnormal cells that grows in or around the brain. Tumors can directly destroy healthy brain cells. They can
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationPeople Living with Cancer
Patient Guide ASCOInformation for People Living with Cancer ADVANCED LUNG CANCER TREATMENT Recommendations of the American Society of Clinical Oncology Welcome The American Society of Clinical Oncology
More informationThe treatment and outcome of patients with soft tissue sarcomas and synchronous metastases
Sarcoma (2002) 6, 69 73 ORIGINAL ARTICLE The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases JOHN M. KANE III, J. WILLIAM FINLEY, DEBORAH DRISCOLL, WILLIAM G. KRAYBILL
More informationThe Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer
BIT's 4th World Cancer Congress 2011 People s Republic of China Dalian The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in treated with DBM therapy Retrospective observational
More informationCorso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationComparison of radiation dose from X-ray, CT, and PET/ CT in paediatric patients with neuroblastoma using a dose monitoring program
Comparison of radiation dose from X-ray, CT, and PET/ CT in paediatric patients with neuroblastoma using a dose monitoring program Poster No.: C-0591 Congress: ECR 2015 Type: Authors: Keywords: DOI: Scientific
More informationElements of PET/CT Reporting
Elements of PET/CT Reporting 1. Clinical History a. Indication i. tumor type ii. abnormality to be evaluated iii. specific clinical question b. Relevent history i. biopsy results ii. chemotherapy iii.
More informationCrosswalk for Positron Emission Tomography (PET) Imaging Codes G0230 G0030, G0032, G0034, G0036, G0038, G0040, G0042, G0044, G0046
Positron Emission Tomography (PET) CPT to HCPCS Level Crosswalk Changes below from CMS Change Request 3741 Transmittals 518 & 31 published on April 1, 2005; mplementation of CPT codes are effective January
More informationLung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
More informationRESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What?
RESEARCH EDUCATE ADVOCATE Just Diagnosed with Melanoma Now What? INTRODUCTION If you are reading this, you have undergone a biopsy (either of a skin lesion or a lymph node) or have had other tests in which
More informationSMALL. 1-800-298-2436 LungCancerAlliance.org
Understanding series SMALL CELL LUNG CANCER 1-800-298-2436 LungCancerAlliance.org A guide for the patient I TABLE OF CONTENTS ANATOMY OF THE LUNGS The following image shows different parts that make up
More informationIntensity-Modulated Radiation Therapy (IMRT)
Scan for mobile link. Intensity-Modulated Radiation Therapy (IMRT) Intensity-modulated radiotherapy (IMRT) uses linear accelerators to safely and painlessly deliver precise radiation doses to a tumor while
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationNon-Small Cell Lung Cancer Therapies
Non-Small Cell Lung Cancer Therapies Guest Expert: Roy, MD, PhD Assistant Professor of Therapeutic Radiology Scott, MD Assistant Professor of Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome
More informationSPECT and PET imaging in porcine inflammation and infection models. UCPH pig model network seminar
SPECT and PET imaging in porcine inflammation and infection models UCPH pig model network seminar Friday November 21. 2014, 8.30 12.00, auditorium A2 70.02, Thorvaldsensvej 40, 1871 Frederiksberg C. See
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationLymphoma. Measurability of Quality Performance Indicators Version 2.0
Lymphoma Measurability of Quality Performance Indicators Version 2.0 To be read in conjunction with: Lymphoma Clinical Quality Performance Indicators (September 2013) Lymphoma Data Definitions V2.0 (September
More informationHow To Treat A Uterine Sarcoma
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition 2001 Uterus: Uterine Sarcomas Jeffrey L. Stern, MD Uterine sarcomas
More informationREPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
More informationIndividual Prediction
Individual Prediction Michael W. Kattan, Ph.D. Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Chairman, Department
More informationThyroid Cancer: Resection, Dissection, Surveillance and Recurrence. Cord Sturgeon, MD
Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence Cord Sturgeon, MD Associate Professor of Surgery Northwestern University Feinberg School of Medicine Director of Endocrine Surgery Chicago,
More informationRadiotherapy in locally advanced & metastatic NSC lung cancer
Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced
More informationEsperienza di stereotassia polmonare al Campus Bio-Medico: tecnica e risultati Rolando M. D Angelillo
Esperienza di stereotassia polmonare al Campus Bio-Medico: tecnica e risultati Rolando M. D Angelillo Università Campus Bio-Medico di Roma - Via Álvaro del Portillo, 21-00128 Roma Italia BED 10 > 100 Gy
More informationProstate Cancer. Treatments as unique as you are
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
More informationCase Report: Whole-body Oncologic Imaging with syngo TimCT
Case Report: Whole-body Oncologic Imaging with syngo TimCT Eric Hatfield, M.D. 1 ; Agus Priatna, Ph.D. 2 ; John Kotyk, Ph.D. 1 ; Benjamin Tan, M.D. 1 ; Alto Stemmer 3 ; Stephan Kannengiesser, Ph.D. 3 ;
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationResponse Criteria for Malignant Lymphoma 2007. Cheson Criteria. Quick Reference Guide
Response Criteria for Malignant Lymphoma 2007 Cheson Criteria Quick Reference Guide Table of Contents Summary of Assessments...3 Baseline Lesion Burden...4 What isameasurable Lesion?...5 Choosing Target
More informationLoco-regional Recurrence
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO AGO e. e. V. V. Loco-regional Recurrence Loco-regional Recurrence Version 2002: Brunnert / Simon Versions 2003 2012: Audretsch
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationWhat is neuroendocrine cervical cancer?
Key Points: 1. Neuroendocrine cancer of the uterine cervix is a rare and aggressive disease. 2. Treatment for neuroendocrine cervical cancer is usually more intensive than that for most other types of
More informationMultiple Myeloma. Abstract. Introduction
Multiple Myeloma Abstract Multiple Myeloma is a plasma cell cancer that causes an overproduction of plasma cells. Multiple Myeloma is a difficult disease to diagnosis because symptoms might not be present
More informationLocoregional recurrence or persistence of papillary carcinoma: radioiodine treatment
Locoregional recurrence or persistence of papillary carcinoma: radioiodine treatment Michele Klain, Marco Salvatore Department of Functional and Biomorphological Science University of Naples "Federico
More informationGeneral Information About Non-Small Cell Lung Cancer
General Information About Non-Small Cell Lung Cancer Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The lungs are a pair of cone-shaped breathing
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Breast cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Breast cancer 2 Clinical background 2 Who
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationDual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions
Skeletal Radiol (2009) 38:451 458 DOI 10.1007/s00256-008-0643-0 SCIENTIFIC ARTICLE Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions Rong Tian & Minggang
More informationMesothelioma. 1. Introduction. 1.1 General Information and Aetiology
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are
More information2011 Radiology Diagnosis Coding Update Questions and Answers
2011 Radiology Diagnosis Coding Update Questions and Answers How can we subscribe to the Coding Clinic for ICD-9 guidelines and updates? The American Hospital Association publishes this quarterly newsletter.
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationAn Update on Lung Cancer Diagnosis
An Update on Lung Cancer Diagnosis Dr Michael Fanning MBBS FRACGP FRACP RESPIRATORY AND SLEEP PHYSICIAN Mater Medical Centre Outline Risk factors for lung cancer Screening for lung cancer Radiologic follow-up
More informationIAEA HumAn HEAltH SErIES
IAEA HumAn HEAltH SErIES no. 9 Appropriate Use of FDG-PET for the Management of Cancer Patients IAEA HUMAN HEALTH SERIES PUBLICATIONS The mandate of the IAEA human health programme originates from Article
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More informationThe following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
More informationLaparoscopic Ultrasonography Assisted Retroperitoneal Lymph Node Sampling in Patients Evaluated for Stomach Cancer Recurrence
Case Series Laparoscopic Ultrasonography Assisted Retroperitoneal Lymph Node Sampling in Patients Evaluated for Stomach Cancer Recurrence Honsoul Kim, MD, Woo Jin Hyung, MD, Joon Seok Lim, MD, Mi-Suk Park,
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationLYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis
LYMPHOMA IN DOGS Lymphoma is a relatively common cancer in dogs. It is a cancer of lymphocytes (a type of white blood cell) and lymphoid tissues. Lymphoid tissue is normally present in many places in the
More information